Rising trends in pancreatic cancer incidence and mortality in 2000&amp;ndash;2014

Wu, Wenrui; He, Xingkang; Yang, Liya; Wang, Qing; Bian, Xiaoyuan; Ye, Jianzhong; Li, Yating

doi:10.2147/clep.s160018

Cited by 79 publications

(62 citation statements)

References 26 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are consistent with other studies of Asian patients that reported an increase in incidence and mortality rates in the last 20 years. Wu et al concluded that age-adjusted incidence and incidence-based mortality for PAC increased during 2000-2014, whereas mortality rates increased during 2000-2005 but decreased during 2005-2014 [22]. According to their findings, based on 119,412 cases of PAC extracted from 18 SEER registries, both incidence and mortality trends increased during the study period, irrespective of ethnicity [22].…”

Section: Discussionmentioning

confidence: 99%

“…Wu et al concluded that age-adjusted incidence and incidence-based mortality for PAC increased during 2000-2014, whereas mortality rates increased during 2000-2005 but decreased during 2005-2014 [22]. According to their findings, based on 119,412 cases of PAC extracted from 18 SEER registries, both incidence and mortality trends increased during the study period, irrespective of ethnicity [22]. In China, there was a significant increase in newly diagnosed pancreatic cancer cases and pancreatic cancer-attributed deaths from 2009 to 2011.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Temporal trends of incidence and mortality in Asian-Americans with pancreatic adenocarcinoma: an epidemiological study

Gad

Găman

Saad

et al. 2020

aog

View full text Add to dashboard Cite

Background Pancreatic cancer is the fourth most common cause of cancer-related deaths in the United States, with an estimated 45,750 deaths in 2019. Mortality outcomes seem to differ based on the ethnicity of the patients, with most studies focusing on the mortality and survival of Caucasians and African Americans. Little attention has been given, however, to Asian-American patients diagnosed with pancreatic adenocarcinoma (PAC). In this study, we aimed to investigate mortality rates in Asian-American patients with PAC. Methods The SEER 13 registries (Surveillance, Epidemiology, and End-Results) of the National Cancer Institute were used to study PAC cases during 1992-2015. The incidence and incidencebased mortality rates per 100,000 person-years, and the annual percentage changes were calculated using SEER*stat software and Joinpoint regression software. Results A total of 5814 PAC cases in Asian-American patients were identified. Most patients were older than 60 years (77.6%) and had metastatic disease (55.8%). The overall incidence of PAC among Asian-Americans was 5.740 per 100,000 person-years (95% confidence interval [CI] 5.592-5.891]. Incidence rates were highest among males and patients older than 60 years. PAC incidence rates among Asian-Americans increased by 1.503% (95%CI 1.051-1.956; P<0.001) per year over the study period. PAC incidence rates increased over the study period for all sex, age, and stage subgroups. PAC incidence-based mortality among Asian-Americans increased by 4.535% (95%CI 3.538-5.541; P<0.001) per year over the study period. Conclusion The incidence of PAC in Asian-Americans, as well as incidence-based mortality rates, are on the rise, irrespective of age, sex or stage subgroup.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Temporal trends of incidence and mortality in Asian-Americans with pancreatic adenocarcinoma: an epidemiological study

Gad

Găman

Saad

et al. 2020

aog

View full text Add to dashboard Cite

show abstract

“…In 2012, the number of patients diagnosed with pancreatic cancer worldwide, according to GLOBOCAN 2012, was 337,872, which means that the incidence increased by 121,046 patients in 6 years [13]. Recent advances in imaging and other diagnostic tools may have contributed to the apparent increase in pancreatic cancer incidence because more patients are diagnosed in the early stages of the disease [14]. This may have also affected the 5-year survival estimates.…”

Section: Trendsmentioning

confidence: 99%

Pancreatic cancer trends in Europe: epidemiology and risk factors

Hawksworth¹,

Hales²,

Martínez³

et al. 2019

View full text Add to dashboard Cite

Pancreatic cancer is the 12 th most common cancer worldwide and the seventh leading cause of cancer-related deaths worldwide. However, it is the seventh most common cancer in Europe. The estimated number of cases of pancreatic cancer worldwide in 2018 was 458,918 with a male to female ratio of 1:1.13. Among those 458,918 patients, 132,559 cases were found in Europe. Rates of pancreatic cancer are 3-4 times higher in the developed world. With incidence and mortality rates being very close, pancreatic cancer is considered one of the deadliest of all cancers. Lifestyle in developed nations, including the rise in physical inactivity and obesity, tobacco smoking, consumption of alcohol, dietary factors, and occupational exposures, may be responsible for the increased incidence of pancreatic cancer. Updated statistics on the epidemiology of pancreatic cancer along with a better understanding of the risk factors are essential for the primary prevention of this disease. Streszczenie Rak trzustki jest dwunastym najczęściej występującym nowotworem i siódmą główną przyczyną zgonów związanych z rakiem na świecie. Jest to także siódmy najczęściej występujący nowotwór w Europie. Liczba przypadków raka trzustki na świecie w 2018 roku wynosiła 458 918, przy stosunku mężczyzn do kobiet 1 : 1,13. W Europie stwierdzono 132 559 przypadków. Występowanie raka trzustki jest 3-4 razy częstsze w krajach rozwiniętych. Ponieważ częstość występowania i śmiertelność są bardzo zbliżone, rak trzustki jest uważany za jeden z najbardziej śmiertelnych nowotworów. Styl życia w krajach rozwiniętych, w tym brak aktywności fizycznej i otyłość, palenie tytoniu, spożywanie alkoholu, czynniki dietetyczne i narażenie zawodowe, może odpowiadać za zwiększoną częstość występowania raka trzustki. Zaktualizowanie statystyki dotyczącej raka trzustki oraz lepsze zrozumienie czynników ryzyka są niezbędne do zapobiegania tej chorobie.

show abstract

“…Pancreatic Ductal Adenocarcinoma (PDA) is the most common form of pancreatic malignancy but is typically diagnosed only in late-stage disease, hence both the incidence and deaths attributable to PDA continue to increase (7,8). At present, there is no clinical procedure that can accurately detect early asymptomatic PDA, largely due to the lack of specific biomarkers of disease (9,10), hence there is an urgent need for better predictors of tumour development and progression in this patient group with extremely poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

ERO1α promotes hypoxic tumour progression and is associated with poor prognosis in pancreatic cancer

Gupta

Park

Tse

et al. 2019

Preprint

View full text Add to dashboard Cite

Pancreatic cancer is a leading cause of mortality worldwide due to difficulty detecting earlystage disease and our poor understanding of the mediators that drive the progression of hypoxic solid tumours. We, therefore, used a heavy isotope 'pulse/trace' proteomic approach to determine how hypoxia alters pancreatic tumour expression of proteins that confer treatment resistance, promote metastasis, and suppress host immunity. Using this method, we identified that hypoxia stress stimulates pancreatic cancer cells to rapidly translate proteins that enhance metastasis (NOTCH2, NCS1, CD151, NUSAP1), treatment resistant (ABCB6), immune suppression (NFIL3,WDR4), angiogenesis (ANGPT4, ERO1α, FOS), alter cell metabolic activity (HK2, ENO2), and mediate growth-promoting cytokine responses (CLK3, ANGPTL4). Database mining confirmed that elevated gene expression of these hypoxiainduced mediators is significantly associated with poor patient survival in various stages of pancreatic cancer. Among these proteins, the oxidoreductase enzyme ERO1α was highly sensitive to induction by hypoxia stress across a range of different pancreatic cancer cell lines and was associated with particularly poor prognosis in human patients. Consistent with these data, genetic deletion of ERO1α substantially reduced growth rates and colony formation in pancreatic cancer cells when assessed in a series of functional assays in vitro. Accordingly, when transferred into a mouse xenograft model, ERO1α-deficient tumour cells exhibited severe growth restriction and negligible disease progression in vivo. Together, these data indicate that ERO1α is potential prognostic biomarker and novel drug target for pancreatic cancer therapy.

show abstract

Rising trends in pancreatic cancer incidence and mortality in 2000–2014

Cited by 79 publications

References 26 publications

Temporal trends of incidence and mortality in Asian-Americans with pancreatic adenocarcinoma: an epidemiological study

Temporal trends of incidence and mortality in Asian-Americans with pancreatic adenocarcinoma: an epidemiological study

Pancreatic cancer trends in Europe: epidemiology and risk factors

ERO1α promotes hypoxic tumour progression and is associated with poor prognosis in pancreatic cancer

Contact Info

Product

Resources

About